|
[Related PubMed/MEDLINE]
Total Number of Papers: 14865
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: ER |
| Long Form |
: estrogen receptor |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. |
--- |
| 2 |
2020 |
Accelerated Tissue Processing With Minimal Formalin Fixation Time for 9-Gauge Vacuum-Assisted Breast Biopsy Specimens. |
HER2, PR, VAB |
| 3 |
2020 |
Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: Quantification of the mediating effects of fasting insulin and free estradiol. |
BMI, CI, IDE, IIE, RR |
| 4 |
2020 |
Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer. |
CNB, CR, HER2, PR |
| 5 |
2020 |
APOBEC3B expression in breast cancer cell lines and tumors depends on the estrogen receptor status. |
A3A, A3B |
| 6 |
2020 |
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response. |
CRISPR |
| 7 |
2020 |
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. |
HR, LRR, PR |
| 8 |
2020 |
Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer. |
AI, AR, CBR, ORR, PFS |
| 9 |
2020 |
Binding specificities of estrogen receptor with perfluorinated compounds: A cross species comparison. |
PFCs |
| 10 |
2020 |
Bioinformatics Analysis of Metabolomics Data Unveils Association of Metabolic Signatures with Methylation in Breast Cancer. |
BC, pam, PAM, SAM |
| 11 |
2020 |
Blocking of Estradiol Receptors ERalpha, ERbeta and GPER During Development, Differentially Alters Energy Metabolism in Male and Female Rats. |
--- |
| 12 |
2020 |
Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. |
OS |
| 13 |
2020 |
Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer. |
MBC, Mo-MDSCs |
| 14 |
2020 |
Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. |
DFS, HER2, PMC, PR |
| 15 |
2020 |
Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. |
BC, BCSS, HR, PR |
| 16 |
2020 |
Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer. |
EPI, ES, NP, PTX |
| 17 |
2020 |
Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers. |
BMI, HER2, NCCN, PR, RS, TNM |
| 18 |
2020 |
Curcumin rescues breast cells from epithelial‑mesenchymal transition and invasion induced by anti‑miR‑34a. |
EMT, HER2, PgR |
| 19 |
2020 |
Current shreds of evidence on the anticancer role of EGCG in triple negative breast cancer: an update of the current state of knowledge. |
EGCG, HER2, PR, TNBC |
| 20 |
2020 |
Development of A 3D Tissue Slice Culture Model for the Study of Human Endometrial Repair and Regeneration. |
PR |
| 21 |
2020 |
Development of CAPER peptides for the treatment of triple negative breast cancer. |
AP-1, HER2, PR, TNBC |
| 22 |
2020 |
Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk. |
ADC, DWI, HER2, OR, RS |
| 23 |
2020 |
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. |
DCIS, PgR |
| 24 |
2020 |
Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis. |
BC, DEGs, ESR1, KM, PgR, RFS |
| 25 |
2020 |
Estrogen receptors differentially regulate intracellular calcium handling in human nonasthmatic and asthmatic airway smooth muscle cells. |
ASM |
| 26 |
2020 |
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. |
HER2, MS, NaCT, pCR, RS |
| 27 |
2020 |
Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling. |
GPX1, PR, TNBC |
| 28 |
2020 |
High expression of soluble CD155 in estrogen receptor-negative breast cancer. |
CTLs, NK, sCD155 |
| 29 |
2020 |
Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer. |
AR, GR, PR |
| 30 |
2020 |
Liposomes and drug-in-cyclodextrin-in-liposomes formulations encapsulating 17beta-estradiol: An innovative drug delivery system that prevents the activation of the membrane-initiated steroid signaling (MISS) of estrogen receptor alpha. |
DCL, MISS |
| 31 |
2020 |
Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway. |
--- |
| 32 |
2020 |
MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. |
BC, MAGUK, TNBC |
| 33 |
2020 |
Metabolism of cyclic phenones in rainbow trout in vitro assays. |
CBP, CPK, rt, VTG |
| 34 |
2020 |
Methylome and transcriptome analyses reveal insights into the epigenetic basis for the good survival of hypomethylated ER-positive breast cancer subtype. |
BrCa |
| 35 |
2020 |
pH-responsive allochroic nanoparticles for the multicolor detection of breast cancer biomarkers. |
Ab, BSA, HER2, PR |
| 36 |
2020 |
Plumbagin inhibited AKT signaling pathway in HER-2 overexpressed-endocrine resistant breast cancer cells. |
NCOA3, p-AKT, PLB |
| 37 |
2020 |
Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5years after diagnosis and late recurrence. |
NLR |
| 38 |
2020 |
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. |
--- |
| 39 |
2020 |
Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. |
PR |
| 40 |
2020 |
Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer. |
OS, PgR, SNPs |
| 41 |
2020 |
Prognostic genes of triple-negative breast cancer identified by weighted gene co-expression network analysis. |
DEG, gipc1, HES6, MYLK2, OS, PPAN, PR, TNBC, WGCNA |
| 42 |
2020 |
Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6. |
ABCG2, CAFs, CM |
| 43 |
2020 |
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. |
DDFS, SPBC, TILs |
| 44 |
2020 |
Selective activation of estrogen receptor beta alleviates cerebral ischemia neuroinflammatory injury. |
MCAO-R, OGD-R |
| 45 |
2020 |
Selective estrogen receptor (ER)beta activation provokes a redistribution of fat mass and modifies hepatic triglyceride composition in obese male mice. |
CD, DIP, HFD |
| 46 |
2020 |
Sex-specific estrogen regulation of hypothalamic astrocyte estrogen receptor expression and glycogen metabolism in rats. |
AMPK, GPER, GS |
| 47 |
2020 |
Steroidogenic acute regulatory protein transcription is regulated by estrogen receptor signaling in largemouth bass ovary. |
ChIP, ESR1, hCG, StAR |
| 48 |
2020 |
Tamoxifen-induced hepatotoxicity via lipid accumulation and inflammation in zebrafish. |
--- |
| 49 |
2020 |
Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society. |
DFS, HER2 |
| 50 |
2020 |
The ancient Chinese formula Longdan Xiegan Tang improves antipsychotic-induced hyperprolactinemia by repairing the hypothalamic and pituitary TGF-beta1 signaling in rats. |
D2R, LXT, TGF |
| 51 |
2020 |
The association of modifiable breast cancer risk factors and somatic genomic alterations in breast tumors: The Cancer Genome Atlas Network. |
BMI, SBS, SCNV, TSMB |
| 52 |
2020 |
[Expression of HMGB1 protein in breast cancer and its clinicopathological significance]. |
HMGB1, PR |
| 53 |
2019 |
17beta-Estradiol Activates HSF1 via MAPK Signaling in ERalpha-Positive Breast Cancer Cells. |
HSF1 |
| 54 |
2019 |
17beta-estradiol at low concentrations attenuates the efficacy of tamoxifen in breast cancer therapy. |
--- |
| 55 |
2019 |
17beta-Estradiol nongenomically induces vascular endothelial H2S release by promoting phosphorylation of cystathionine gamma-lyase. |
CSE, HUVECs, pGC-A, PKGI |
| 56 |
2019 |
17beta-Estradiol protects mesenchymal stem cells against high glucose-induced mitochondrial oxidants production via Nrf2/Sirt3/MnSOD signaling. |
hUCB-MSCs, MnSOD, mtROS |
| 57 |
2019 |
18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT. |
18F-FDG, 18F-FES, CT, PET |
| 58 |
2019 |
18F-fluorodeoxyglucose PET/computed tomography in locoregional staging and assessment of biological and clinical aggressiveness of breast cancer subtypes. |
18F-FDG, ALN, AUC, CT, NPV, PPV, PR |
| 59 |
2019 |
18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-alpha Mutations in Breast Cancer. |
18F-FES, WT |
| 60 |
2019 |
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. |
BC |
| 61 |
2019 |
21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. |
RS, SEER |
| 62 |
2019 |
24R,25-Dihydroxyvitamin D3 regulates breast cancer cells in vitro and in vivo. |
--- |
| 63 |
2019 |
A Case of Locally Advanced Breast Cancer in a 59-Year-Old Man Requiring a Modified Approach to Management. |
HER2, PR |
| 64 |
2019 |
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. |
CN, FISH, WT |
| 65 |
2019 |
A deletion mutation within the ATBF1 gene is strongly associated with goat litter size. |
SWCG |
| 66 |
2019 |
A functional single nucleotide polymorphism in ABCC11, rs17822931, is associated with the risk of breast cancer in Japanese. |
ABC, CIs, HERPACC II, ORs, SNP |
| 67 |
2019 |
A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). |
BCS, BCSS, DCIS, ET, FSM, LR, RT |
| 68 |
2019 |
A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study. |
AUC, CNB, HER2, PR |
| 69 |
2019 |
A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer. |
CI, HER2, LVI, ODX, PR |
| 70 |
2019 |
A nongenomic mechanism for "metalloestrogenic" effects of cadmium in human uterine leiomyoma cells through G protein-coupled estrogen receptor. |
Cd, EGFR, GPER, HB-EGF, MMP2, si |
| 71 |
2019 |
A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting gamma-secretase-mediated activation of Notch signaling. |
BC, EMT, GSIs, NICD, PR |
| 72 |
2019 |
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. |
AUC, NOLUS, PR |
| 73 |
2019 |
A Pooled Analysis of Breastfeeding and Breast Cancer Risk by Hormone Receptor Status in Parous Hispanic Women. |
CIs, ORs, PR |
| 74 |
2019 |
A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy. |
lncRNAs |
| 75 |
2019 |
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). |
pCR, RCB |
| 76 |
2019 |
A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB). |
CI, HR, NCDB, OS, PSM |
| 77 |
2019 |
A Retrospective Study of the Imaging and Pathological Features of Metaplastic Breast Carcinoma and Review of the Literature. |
ADC, DWI, MBC, MRI, PR, T2WI, TIC |
| 78 |
2019 |
A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. |
TDO, TNBC |
| 79 |
2019 |
A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis. |
BC, BCSS, sTILs, TNBCs |
| 80 |
2019 |
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. |
--- |
| 81 |
2019 |
Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer. |
AI, BRCA2, DEGs, GO, RAD51 |
| 82 |
2019 |
Abilities of beta-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. |
PDAC |
| 83 |
2019 |
Abnormal expression of estrogen receptor is associated with thin endometrium. |
PR |
| 84 |
2019 |
Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer. |
IHC, NAC, PR |
| 85 |
2019 |
Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. |
HER2, IHC, RT-PCR |
| 86 |
2019 |
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. |
--- |
| 87 |
2019 |
Activation of hepatic estrogen receptor-alpha increases energy expenditure by stimulating the production of fibroblast growth factor 21 in female mice. |
FGF21 |
| 88 |
2019 |
Acute estradiol treatment reduces skeletal muscle protein breakdown markers in early- but not late-postmenopausal women. |
FOXO3, MHC, MuRF1 |
| 89 |
2019 |
Added value of mean and entropy of apparent diffusion coefficient values for evaluating histologic phenotypes of invasive ductal breast cancer with MR imaging. |
ADC, HER2, IDC, PR |
| 90 |
2019 |
Adrenal Steroids Modulate Fibroblast-Like Synoviocytes Response During B. abortus Infection. |
DHEA, GR, HSD |
| 91 |
2019 |
AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs). |
3-MC, AhR, CAFs, GPER |
| 92 |
2019 |
Akt and estrogen receptor expression in nasal polyps. |
NP |
| 93 |
2019 |
Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). |
BC, BOADICEA, CI, FRP, HR, ProF-SC |
| 94 |
2019 |
Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy. |
AI, AR, PKIB, SGK3 |
| 95 |
2019 |
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. |
AMPK, HER2, PR, TNBC |
| 96 |
2019 |
Amphiregulin mediates the hormonal regulation on Rspondin-1 expression in the mammary gland. |
AREG, RSPO1 |
| 97 |
2019 |
An aptasensor for rapid and sensitive detection of estrogen receptor alpha in human breast cancer. |
ELISA, IHC |
| 98 |
2019 |
An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment. |
--- |
| 99 |
2019 |
An evaluation of fulvestrant for the treatment of metastatic breast cancer. |
ABC, SERD |
| 100 |
2019 |
Analogues of ERbeta ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis. |
IL, OL |
|
A Search Service for Abbreviation / Long Form
